Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, single-blind, placebo controlled study of influenza vaccine in preventing cardiovascular events in post myocardial infarction patients and in those with stable angina pectoris

Next Previous
Trial Profile

Randomized, single-blind, placebo controlled study of influenza vaccine in preventing cardiovascular events in post myocardial infarction patients and in those with stable angina pectoris

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Cardiovascular disorders; Influenza virus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms IVCAD

Most Recent Events

  • 19 May 2009 Incidence of cardiovascular events reported at the 19th International Conference of Clinical Microbiology and Infectious Diseases (ECCMID).
  • 22 Jan 2009 Biomarkers information updated
  • 20 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top